Meazza Cristina, Gertosio Chiara, Pagani Sara, Pilotta Alba, Tinelli Carmine, Buzi Fabio, Farello Giovanni, Genoni Giulia, Bona Gianni, Bozzola Mauro
Pediatrics and Adolescentology Unit, Internal Medicine and Therapeutics Department, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Minerva Endocrinol. 2017 Dec;42(4):325-330. doi: 10.23736/S0391-1977.16.02510-4. Epub 2016 Jun 15.
Patients with childhood-onset GH deficiency (GHD) are usually retested after achievement of near final height, to verify whether they need to continue GH treatment. We investigated if GH stimulation test is necessary to confirm a persistent status of GHD or if other parameters could be a reliable predictor of GHD persistence.
One-hundred and sixty-four children with idiopathic GHD (55 females and 109 males) were retested when they reached near final height using GH releasing hormone (GHRH)+arginine test or arginine alone.
At diagnosis, 23.8% of patients showed severe GHD (GH peak at diagnosis <5 ng/mL) and 76.2% showed partial GHD (GH peak <10 ng/mL). At time of retesting, 82.1% of severe GHD and 82.4% of partial GHD patients showed transient GHD. IGF-I levels were not different between persistent (0.18±1.18 SDS) and transient GHD subjects (0.17±0.82 SDS). Furthermore, among persistent severe GHD patients only two showed very reduced levels of IGF-I (<-2.0 SDS).
The majority of patients idiopathic GHD proved to be transient. IGF-I levels alone do not discriminate subjects with persistent from those with transient GHD. Therefore, after the end of GH substitutive treatment, a re-evaluation of GH secretion is mandatory to verify the persistence of GHD in adulthood.
儿童期起病的生长激素缺乏症(GHD)患者通常在接近最终身高时进行重新检测,以确定他们是否需要继续生长激素治疗。我们研究了生长激素刺激试验对于确认GHD持续状态是否必要,或者其他参数是否可以作为GHD持续存在的可靠预测指标。
164例特发性GHD儿童(55例女性,109例男性)在接近最终身高时使用生长激素释放激素(GHRH)+精氨酸试验或仅用精氨酸进行重新检测。
诊断时,23.8%的患者表现为严重GHD(诊断时生长激素峰值<5 ng/mL),76.2%表现为部分GHD(生长激素峰值<10 ng/mL)。重新检测时,82.1%的严重GHD患者和82.4%的部分GHD患者表现为暂时性GHD。持续性GHD患者(0.18±1.18 SDS)和暂时性GHD患者(0.17±0.82 SDS)的胰岛素样生长因子-I(IGF-I)水平无差异。此外,在持续性严重GHD患者中,只有2例IGF-I水平极低(<-2.0 SDS)。
大多数特发性GHD患者被证明是暂时性的。仅IGF-I水平无法区分持续性GHD患者和暂时性GHD患者。因此,在生长激素替代治疗结束后,必须重新评估生长激素分泌情况,以确认成年期GHD是否持续存在。